Topical Non-Steroidal Anti-Inflammatory Drugs in Allergic Conjunctivitis: Meta-Analysis of Randomized Trial Data

REFERENCES

• Calonge M. Classification of ocular atopic/allergic disorders and conditions: An unsolved problem. Acta Ophthalmol Scand Suppl 1999; 228: 10–13
   Google Scholar
• Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmol 2003; 217(2)89–98
   Google Scholar
• Uchio E. Possibility of non-steroidal treatment in allergic conjunctival diseases. Allerg Internat 2004; 53(4)315–319
   Google Scholar
• Helleboid L. Treatment of allergic conjunctivitis and keratoconjunctivitis summary. Revue Francaise d'Allergologie et d'Immunologie Clinique 2004; 44(1)71–75
   Google Scholar
• Hingorani M, Lightman S. Therapeutic options in ocular allergic disease. Drugs 1995; 50(2)208–221
   PubMed Web of Science ®Google Scholar
• Bielory L. Ocular allergy guidelines: a practical treatment algorithm. Drugs 2002; 62(11)1611–1634
   PubMed Web of Science ®Google Scholar
• Al Yusuf N SH, Al Alawi E K. The effect of diclofenac sodium on allergic conjunctivitis. J Bahrain Med Soc 1999; 11(2)26–31
   Google Scholar
• Avunduk A M, Avunduk M C, Varnell E D, Kaufman H E. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients:A clinical and immunocytochemical study.[see comment]. Am J Ophthalmol 2003; 136(4)593–602
   PubMed Web of Science ®Google Scholar
• D'Angelo G, Lambiase A, Cortes M, Sgrulletta R, Pasqualetti R, Lamagna A, Bonini S. Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. Graefes Arch Clin Exper Ophthalmol 2003; 241(3)192–195
   PubMedGoogle Scholar
• Deschenes J, Discepola M, Abelson M. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta OphthalmolScandSuppl 1999; 228: 47–52
   Google Scholar
• Discepola M, Deschenes J, Abelson M. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol ScandiSuppl 1999; 228: 43–46
   Google Scholar
• James I G, Campbell L M, Harrison J M, Fell P J, Ellers–Lenz B, Petzold U. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opin 2003; 19(4)313–320
   PubMed Web of Science ®Google Scholar
• Leonardi A, Busato F, Fregona I, Plebani M, Secchi A G. Anti-inflammatory and antiallergic effects of ketorolac tromethamine in the conjunctival provocation model. Br J Ophthalmol 2000; 84(11)1228–1232
   PubMedGoogle Scholar
• Miyake-Kashima M, Takano Y, Tanaka M, Satake Y, Kawakita T, Dogru M, Asano-Kato N, Fukagawa K, Fujishima H. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Japan J Ophthalmol 2004; 48(6)587–590
   PubMed Web of Science ®Google Scholar
• Notivol R, Martinez M, Bergamini M V. Treatment of chronic nonbacterial conjunctivitis with a cyclo-oxygenase inhibitor or a corticosteroid. Pranoprofen Study Group. Am J Ophthalmol 1994; 117(5)651–656
   PubMedGoogle Scholar
• Shulman D G, Amdahl L, Washington C, Graves A. A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents. Clin Therapeut. 2003; 25(4)1096–1106
   PubMed Web of Science ®Google Scholar
• Tauber J, Raizman M B, Ostrov C S, Laibovitz R A, Abelson M B, Betts J G, Koester J M, Gill D, Schaich L. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocular Pharmacol Therapeu 1998; 14(2)137–145
   PubMedGoogle Scholar
• Ciprandi G, Cerqueti P M, Sacca S, Ciurlo G, Tosca M A, Canonica G W. Non-steroidal treatment of pollen-induced conjunctivitis: Comparison of different pharmacological protocols. Allergy 1991; 46(5)393–395
   PubMedGoogle Scholar
• Ballas Z, Blumenthal M, Tinkelman D G, Kriz R, Rupp G. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993; 141–148, 38 Suppl
   PubMedGoogle Scholar
• Donshik P C, Pearlman D, Pinnas J, Raizman M B, Tauber J, Tinkelman D, Walters T R. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis. Adv Ther. 2000; 17(2)94–102
   PubMedGoogle Scholar
• Laibovitz R A, Koester J, Schaich L, Reaves T A. Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. J Ocul Pharmacol Therapeu 1995; 11(3)361–368
   PubMedGoogle Scholar
• Sharma A, Gupta R, Ram J, Gupta A. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol 1997; 45(3)177–180
   PubMedGoogle Scholar
• Sud R N, Greval R S, Bajwa R S. Topical flurbiprofen therapy in vernal keratoconjunctivitis. Indian J Med Sci 1995; 49(9)205–209
   PubMedGoogle Scholar
• Tinkelman D G, Rupp G, Kaufman H, Pugely J, Schultz N. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993; 133–140, 38 Suppl
   PubMedGoogle Scholar
• Yaylali V, Demirlenk I, Tatlipinar S, Ozbay D, Esme A, Yildirim C, Ozden S. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand 2003; 81(4)378–382
   PubMedGoogle Scholar
• Ciprandi G, Buscaglia S, Cerqueti M P, Sacca S, Tosca M, Canonica G W. Topical anti-inflammatory drugs in the treatment of allergic pollinosic conjunctivitis: a comparative double-blind study. J InvestigationAllergology Clinl Immunol 1992; 2(5)248–252
   Google Scholar
• Sharir M. Exacerbation of asthma by topical diclofenac. Arch Ophthalmol 1997; 115(2)294–295
   PubMedGoogle Scholar
• Sheehan G J, Kutzner M R, Chin W D. Acute asthma attack due to ophthalmic indomethacin. Ann InternMed 1989; 111(4)337–338
   PubMed Web of Science ®Google Scholar
• Uchio E, Kadonosono K. Acute asthma attack caused by ophthalmic application of antiallergic agents. Japan J Ophthalmol 2004; 48(5)475–477
   PubMedGoogle Scholar